Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 11-17

  Mellstedt, Håkan ^a   Vansteenkiste, Johan ^b   Thatcher, Nick ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Immune response; Immunotherapy; NSCLC; Therapeutic cancer vaccine; Tumor antigen

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; CIMAVAX; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; L BLP25; LUCANIX; MELANOMA ANTIGEN 3; MUCIN 1; NAVELBINE; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; STIMUVAX; TG 4010; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; REVIEW; TUMOR CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS;

EID: 79957709717     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.02.023     Document Type: Review

References (87)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, [June 17, EPub ahead of print].
2. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
3. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
4. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
5. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
6. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
7. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
8. Takeda K., Hida T., Sato T., Ando M., Seto T., Satouchi M., et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010, 28:753-760.
9. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
10. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
11. Chaudhuri D., Suriano R., Mittelman A., Tiwari R.K. Targeting the immune system in cancer. Curr Pharm Biotechnol 2009, 10:166-184.
12. Emens L.A., Jaffee E.M. Cancer vaccines: an old idea comes of age. Cancer Biol Ther 2003, 2:S161-S168.
13. Goldman B., DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 2009, 27:129-139.
14. Bradbury P.A., Shepherd F.A. Immunotherapy for lung cancer. J Thorac Oncol 2008, 3:S164-S170.
15. Dermime S., Armstrong A., Hawkins R.E., Stern P.L. Cancer vaccines and immunotherapy. Br Med Bull 2002, 62:149-162.
16. Nencioni A., Gruenbach F., Patrone F., Brossart P. Anticancer vaccination strategies. Ann Oncol 2004, 15(Suppl. 4):iv153-iv160.
17. Igney F.H., Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002, 71:907-920.
18. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
19. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006, 16:3-15.
20. Widen K., Mozaffari F., Choudhury A., Mellstedt H. Overcoming immunosuppressive mechanisms. Ann Oncol 2008, 19(Suppl. 7):vii241-vii247.
21. Ho C., Ochsenbein A.F., Gautschi O., Davies A.M. Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 2008, 9(Suppl. 1):S20-S27.
22. Thomas D.A., Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
23. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
24. Kochenderfer J.N., Gress R.E. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood) 2007, 232:1130-1141.
25. Cluff C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2009, 667:111-123.
26. Gridelli C., Rossi A., Maione P., Ferrara M.L., Castaldo V., Sacco P.C. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009, 14:909-920.
27. Sotomayor E.M., Borrello I., Rattis F.M., Cuenca A.G., Abrams J., Staveley-O'Carroll K., et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001, 98:1070-1077.
28. van Mierlo G.J., Boonman Z.F., Dumortier H.M., den Boer A.T., Fransen M.F., Nouta J., et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 2004, 173:6753-6759.
29. Morton D.L., Mozzillo N., Thompson J.F., Kelley M.C., Faries M., Wagner J., et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007, 25(18S). [abstract 8508].
30. Itoh K., Yamada A., Mine T., Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009, 39:73-80.
31. Brichard V.G., Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007, 25(Suppl. 2):B61-71.
32. Altin J.G., van Broekhoven C.L., Parish C.R. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity. Expert Opin Biol Ther 2004, 4:1735-1747.
33. Sangha R., Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007, 13:S4652-S4654.
34. Zang X., Allison J.P. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007, 13:5271-5279.
35. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
36. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
37. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
38. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280.
39. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
40. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
41. Wood C., Srivastava P., Bukowski R., Lacombe L., Gorelov A.I., Gorelov S., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145-154.
42. Schuster S.J., Neelapu S.S., Gause B.L., Muggia F.M., Gockerman J.P., Sotomayor E.M., et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol 2009, 17(18S). [abstract 2].
43. Schwartzentruber D.J., Lawson D., Richards J., Conry R.M., Miller D., Triesman J., et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009, 27(18S). [abstract CRA9011].
44. Eggermont A.M., Suciu S., Rutkowski P., Marsden J., Testori A., Corrie P., et al. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J Clin Oncol 2010, 28(15s). [abstract 8505].
45. Kim J., Raz D., Jablons D. Unmet need in lung cancer: can vaccines bridge the gap?. Clin Lung Cancer 2008, 9(Suppl. 1):S6-S12.
46. Miller P.W., Sharma S., Stolina M., Butterfield L.H., Luo J., Lin Y., et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000, 11:53-65.
47. Yasumoto K., Hanagiri T., Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 2009, 57:449-457.
48. Raez L.E., Fein S., Podack E.R. Lung cancer immunotherapy. Clin Med Res 2005, 3:221-228.
49. Nemunaitis J., Dillman R.O., Schwarzenberger P.O., Senzer N., Cunningham C., Cutler J., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006, 24:4721-4730.
50. Rook A.H., Kehrl J.H., Wakefield L.M., Roberts A.B., Sporn M.B., Burlington D.B., et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986, 136:3916-3920.
51. Tzai T.S., Shiau A.L., Liu L.L., Wu C.L. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res 2000, 20:1557-1562.
52. Fakhrai H., Tong A., Nemunaitis J., Shawler D.L. Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. J Clin Oncol 2009, 27(15S). [abstract 3013].
53. NCT00676507. Phase III Lucanix™ vaccine therapy in advanced non-small cell lung cancer (NSCLC) following front-line chemotherapy (STOP trial). [updated 25.03.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00676507?term=STOP+belagenpumatucel&rank=1.
54. Ciardiello F., De Vita F., Orditura M., Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2004, 16:130-135.
55. Nakamura H., Kawasaki N., Taguchi M., Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006, 61:140-145.
56. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
57. Gonzalez G., Crombet T., Catala M., Mirabal V., Hernandez J.C., Gonzalez Y., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998, 9:431-435.
58. Neninger Vinageras E., de la Torre A., Osorio Rodriguez M., Catala Ferrer M., Bravo I., Mendoza del Pino M., et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:1452-1458.
59. Rodriguez P.C., Rodriguez G., Gonzalez G., Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 2010, 12:17-23.
60. NCT00516685. Vaccine therapy in treating patients with non-small cell lung cancer (NSCLC) stages IIIB/IV. [updated 29.01.2009]. http://www.clinicaltrials.gov/ct2/show/NCT00516685?term=EGF+vaccine&rank=1.
61. Sienel W., Varwerk C., Linder A., Kaiser D., Teschner M., Delire M., et al. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 2004, 25:131-134.
62. Vansteenkiste J., Zielinski H., Linder A., Dahabre J., Esteban E., Malinowski W., et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007, 25(18S). [abstract 7554].
63. NCT00480025. GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer (MAGRIT trial). [updated 24.03.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00480025?term=MAGE-A3&rank=8.
64. Vlad A.M., Kettel J.C., Alajez N.M., Carlos C.A., Finn O.J. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004, 82:249-293.
65. Grinstead J.S., Koganty R.R., Krantz M.J., Longenecker B.M., Campbell A.P. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions. Biochemistry 2002, 41:9946-9961.
66. Agrawal B., Longenecker B.M. MUC1 mucin-mediated regulation of human T cells. Int Immunol 2005, 17:391-399.
67. Raina D., Ahmad R., Kumar S., Ren J., Yoshida K., Kharbanda S., et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 2006, 25:3774-3783.
68. Shen Q., Rahn J.J., Zhang J., Gunasekera N., Sun X., Shaw A.R., et al. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1. Mol Cancer Res 2008, 6:555-567.
69. Agrawal B., Krantz M.J., Reddish M.A., Longenecker B.M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998, 4:43-49.
70. Guddo F., Giatromanolaki A., Koukourakis M.I., Reina C., Vignola A.M., Chlouverakis G., et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998, 51:667-671.
71. Macdermed D.M., Khodarev N.N., Pitroda S.P., Edwards D.C., Pelizzari C.A., Huang L., et al. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 2010, 3:16.
72. Woenckhaus M., Merk J., Stoehr R., Schaeper F., Gaumann A., Wiebe K., et al. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 2008, 39:126-136.
73. Hirasawa Y., Kohno N., Yokoyama A., Kondo K., Hiwada K., Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000, 161:589-594.
74. Ramlau R., Quoix E., Rolski J., Pless M., Lena H., Levy E., et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008, 3:735-744.
75. Ramlau R., Westeel V., Papai Z., Riviere A., Madroszyk A., Koralewski P., et al. Randomized phase IIb trial evaluating the therapeutic vaccine TG4010(MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26(15S). [abstract 8023].
76. Acres B., Quoix E., Ramlau R., Lacoste G., Marie Bastien B., Tavernaro A., et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol 2009, 27(15S). [abstract 3027].
77. NCT00415818. Immunotherapy with TG4010 in patients with advanced non-small cell lung cancer. [updated 02.09.2010]. http://www.clinicaltrials.gov/ct2/show/NCT00415818?term=TG4010&rank=1.
78. Transgene. TG4010(MVA-MUC-1-IL2). [accessed 29.03.2011]. http://transgene.fr/.
79. Guan H.H., Budzynski W., Koganty R.R., Krantz M.J., Reddish M.A., Rogers J.A., et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998, 9:451-458.
80. North S., Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 2005, 4:249-257.
81. Palmer M., Parker J., Modi S., Butts C., Smylie M., Meikle A., et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001, 3:49-57. [discussion 8].
82. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulieres D., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23:6674-6681.
83. Butts C., Maksymiuk A., Goss G., Soulieres D., Marshall E., Cormier Y., et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. J Thorac Oncol 2007, 2(Suppl. 4):S332-S333. [abstract B1-01].
84. Butts C., Anderson H., Maksymiuk A., Vergidis D., Soulieres D., Cormier Y., et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(15S). Abstract 3055.
85. Butts C., Murray N., Smith C.J., Ellis P.M., Jasas K., Maksymiuk A., et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine (L-BLP25) in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 2010, 11:391-395.
86. NCT00409188. Cancer vaccine study for unresectable stage III non-small cell lung cancer (START trial). [updated 23.02.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00409188?term=00409188&rank=1.
87. NCT01015443. Cancer vaccine study for stage III, unresectable, non-small cell lung cancer (NSCLC) in the Asian population (INSPIRE trial). [updated 03.02.2011]. http://clinicaltrials.gov/ct2/show/NCT01015443.